Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer.


First disclosure of our CCR8 antagonist IPG7236 and its optimization story in Journal of Medicinal Chemistry. The compound exhibited excellent PK profile in human as well as promising anti-tumor activity in Phase I and will be advanced into Phase II stage soon.

点击30.pngClick here to learn more